Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Alaunos Therapeutics ( (TCRT) ) has shared an update.
On August 19, 2025, Alaunos Therapeutics announced that it had regained compliance with Nasdaq’s continued listing requirements after previously receiving a notice of non-compliance on April 7, 2025. The company addressed the issue by increasing its stockholders’ equity to $3.66 million by June 30, 2025, surpassing the minimum requirement of $2.5 million, thereby securing its position on the Nasdaq Capital Market.
Spark’s Take on TCRT Stock
According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral.
Alaunos Therapeutics’ overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.
To see Spark’s full report on TCRT stock, click here.
More about Alaunos Therapeutics
Alaunos Therapeutics, Inc. operates in the biotechnology industry, focusing on developing innovative therapies for cancer treatment. The company is involved in advancing its proprietary T-cell receptor therapy platform to target solid tumors.
Average Trading Volume: 44,789
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.11M
For a thorough assessment of TCRT stock, go to TipRanks’ Stock Analysis page.